· AIM:Toinvestigatetheantiangiogeniceffectsandsafety oftopicallyadministeredlow-molecular-weightheparin-taurocholate7 (LHT7)oncornealneovascularization (CoNV).
INTRODUCTION
I nordertocontrolcornealneovascularization(CoNV), variousstrategiesincludingthemedicalmodalities including the applicationofsteroids,cyclosporinA, methotrexate,andnon-steroidalanti-inflammatorydrugs; photodynamictherapy;fineneedlediathermy;argonlaser photocoagulationandhavebeenattempted [1] [2] [3] [4] [5] [6] [7] [8] [9] .Thesystemic orintravitreal anti-vascular endothelialgrowthfactor (VEGF) monoclonal antibody,bevacizumab(Avastin; Roche,Basel,Switzerland)isinjectedtosuccessfullytreat retinopathyofprematurity,age-relatedmaculardegeneration, andmacularedemacausedbydiabeticretinopathyand retinalveinocclusion [13] [14] [15] [16] .Thetopicaladministrationof bevacizumabcaninhibitCoNV [10] [11] [12] . Heparinantagonizesbloodclottingbycreatingacomplex involvingantithrombinIII [17] [18] .Heparinsulfatebindingto growthfactorsstabilizesthemandattenuatestheiractivation byblockingtheirdiffusionanddiminishingproteolytic degradation [19] [20] .Heparinderivativesarecreatedtonotonly attenuatehemorrhagicadverseeffectsbutalsostrengthenthe beneficialeffectsofheparin,suchasanti-angiogenesis. Low-molecular-weightheparin-taurocholate7 (LHT7)isan low-molecularweightheparin (LMWH)conjugatedwith seventaurocholates,havingapolyprolinehelicalstructure withmorenegativechargesandfacilitatingstrongerbinding togrowthfactors,includingVEGF,thanotherheparin derivatives [21] .TheLHT7moleculeshowsuniquefeatures thatstronglyattenuateVEGF 165 -dependentangiogenesisby antagonizingphosphorylationoftheVEGF 165 receptor. However,bevacizumabisamonoclonalantibodydirectly against VEGF 165 .Werecentlyshowedthatthe subconjunctivalLHT7administrationattenuatesCoNVs usingratchemicalcauterization,despitecomplicationsthat includedcornealstromalhemorrhage [22] .Thissuggestedthat topicalapplicationsofLHT7shouldbeconsideredto overcomethisadverseeffect.Inourpresentstudy,we attemptedtoinvestigatetheeffectsandsafetyoftopically administeredLHT7onCoNVusingthesameratchemical cauterization.Sofar,theantiangiogeniceffectsandsafetyof topicalLHT7havenotpreviouslybeendetermined. MATERIALSANDMETHODS
Allanimalweremanagedinaccordancewiththeguidelines oftheAssociationforResearchinVisionand Ophthalmology StatementfortheUseofAnimalsin
OphthalmicandVisionResearch.Theexperimentalprotocol wasapprovedbytheInstitutionalAnimalCareandUse CommitteeofAsanMedicalCenter,Seoul,Korea. Twentyeighthealthy5-to6-week-oldSprague-Dawleyrats weighing225gto275gwereincluded.Underthedeep anesthesiainducedbyintraperitonealxylazinehydrochloride (10mg/kg)administration,thewholeprocedureswere carriedout.Inadditionwithtopicalanesthesiainducedby 0.5%(wt/vol)proparacainehydrochloride(Alcaine;Alcon laboratories,FortWorth,TX,USA)administration,a chemicalinjurywascreated3mmindiameterbytouching an75%(wt/vol)silvernitrate/25%(wt/vol)potassiumnitrate (ArzolChemical,Keen,NH,USA)-coatedapplicatorstick ontothecentralcorneafor8s [23] .Vigorousirrigationwas carriedoutwith10mLofbalancedsaltsolution(Alcon Laboratories)toremoveremainedsilvernitrate/potassium nitratesolution.Allchemicalinjurieswerecreatedbya singleresearchertomaintaintheconsistencyofchemical injury. Fourty-eighthoursaftertheinjury,thecornealburninjuries werescoredaspreviouslyreported [20] .Onlycorneaswith burninjuryscoresofequalorgreaterthan+2wereinvolved intheevaluationofCoNVscore [24] .Fourof28eyeswere excludedinthefirstweekaftertheinjuryduetoimmoderate intraperitonealanesthesia.Thus,24ratswererandomly dividedtooneoffourgroupsaftercauterization:thelow LHT7group(=6)received0.02mLof12.5mg/mLof LHT7topicallyandthehighLHT7group(=6)received 0.02mLof25mg/mLofLHT7topically.Withregardto randomization,micewererandomizedusingastratified designaccordingtowhichcagetheylived.Withineachcage, theywererandomlyassignedtooneoffourgroups.Asa positivecontrol,ratsinthebevacizumabgroup(=6) received0.02mLof12.5mg/mLofbevacizumabtopically, whereasthoseinthenormalsaline(NS)group(=6) received0.02mLof0.9%(wt/vol))ofNStopicallyasa negativecontrol.Inallgroups,treatmenteyedropswere topicallyadministeredthreetimesadayfor14dandstarted at48hafterinjuryinductioninallgroups.Thebevacizumab concentrationwaschosenbasedonpreviousreportsto facilitateinter-studycomparisons [12, 25] .Topicaladministrations wereperformedusing20 滋gmicropipettes (PipetmanP; Gilson,Inc.,Paris,France).AllLHT7andbevacizumab eyedropsweremadewithsterileNS.LHT7waskindlygiven byProfessorYoungroByun,CollegeofPharmacy,Seoul NationalUniversity,Seoul,Korea. Alleyeswerecheckedusinganopticalmicroscopyat1and 2wkafterinjuryunderthedeepanesthesia.Allcorneaswere digitallyphotographedusingadigitalcamera(32 伊 magnification;Coolpix4500,NikonImagingJapan,Tokyo, Japan).Theimageanalysisforeachcorneawascarriedout usingtheimagesoftwareprogram(ImageJ;v.1.40;National InstituteofMentalHealth,Bethesda,MD,USA).We calculatedtheareaoftheCoNVinpixelsandscoredthe proportionofthisneovascularizedareawithrespecttothe wholecorneaastheCoNVpercentage [5, [26] [27] [28] [29] Topicalbevacizumabadministrationhasbeenperformed previouslyforthetreatmentofCoNVinrats [24, [30] [31] [32] and rabbits [33] [34] .Inourcurrentstudy,thebevacizumabgroup, receiving12.5mg/mLofthisdrugtopically,wasincludedas apositivecontrol,whilsttheNSgroupasanegativecontrol. Thesame concentrationoftopicalLHT7astopical bevacizumabwasdeterminedtouseinlowLHTgroup, becauseourprevious studyshowedthatthe antiangiogenicity ofsubconjunctivally administedLHT7is equivalenttothatofsubconjunctivally administered bevacizumab [1] . [12] . However,Hashemian [31] havereportedthatboth subconjunctivalandtopicalbevacizumabhaveequalpotency inpreventingCoNVinrats. Intermsofcomplicationsinourcurrentstudy,weobserved noadverseeffects,suchascornealperforationorcorneal stromalhemorrhage,inourLHTgroups.Conversely,we havepreviouslyreportedtwocasesofcornealstromal bleeding,oneineachofalowandhighLHT7groupthat subconjunctivallyreceived0.02and0.04mLof25mg/mL ofLHT7,respectively [22] .Hence,thetopicaladministrationof LHT7isprovingtobelessinvasiveandsaferthanthe subconjunctivalinjectionofthiscompound. Ourstudyhadseverallimitationsofnote.First,the followed-upperiodwasonly2wkafterchemical cauterization,whichwasarelativelyshort.Second,wedid notdeterminetheoptimaldosagefortreatingCoNVby topicalLHT7andfurtherstudiesareneededtoevaluatethe criticalrangeofLHT7concentrationstouseinaclinical application.Finally, thecorneasshouldhave been immunohistochemicallystainedwithspecialantibodies includinganti-CD31antibodyafterwholemountstoget moreaccurateresults [35] ,despiteCoNVscanbeclearly investigatedintheratchemicalcauterizationmodel.We concludefromourcurrentanalyses,however,thatthetopical applicationofLHT7efficientlyattenuatesCoNVafter chemicalcauterizationintheratwithoutproducingadverse effects.
